Feb. 15, 2018
Researchers at the University of New Mexico have developed a pharmaceutical treatment utilizing small molecules to inhibit mechanisms of brain damage from intracerebral hemorrhage (ICH)/hemorrhagic stroke (HS).
The invention identifies a zinc specific chelator capable of inhibiting zinc insertion into protoporphyrin, greatly decreasing intracerebral hemorrhage (ICH)-induced endogenous zinc protoporphyrin (ZnPP) production. ZnPP accumulation is prevalent in surrounding brain tissue, following ICH-induced brain damage; therefore, since the chelator can be readily inhibited by small molecules, this may provide a treatment target for ICH therapy.
Stroke is a leading cause of death and adult disability in the world. The second most prevalent type of stroke, known as intracerebral hemorrhage (ICH) and hemorrhagic stroke (HS), has the poorest prognosis of all stroke subtypes and is responsible for about 40 percent of all stroke deaths. The lysis of red blood cells, hemin release, and overload of iron are recognized as the primary causes of ICH-induced brain damage. There are currently no treatments available for ICH, as the cellular mechanisms behind ICH-induced brain damage are only partially understood. However, recent discoveries have emerged exploiting the underlying relationship between the accumulation of zinc and brain damage.
Researchers at the University of New Mexico have developed a pharmaceutical treatment utilizing small molecules to inhibit mechanisms of brain damage from intracerebral hemorrhage (ICH)/hemorrhagic stroke (HS). The invention identifies a zinc specific chelator capable of inhibiting zinc insertion into protoporphyrin, greatly decreasing intracerebral hemorrhage (ICH)-induced endogenous zinc protoporphyrin (ZnPP) production. ZnPP accumulation is prevalent in surrounding brain tissue, following ICH-induced brain damage; therefore, since the chelator can be readily inhibited by small molecules, this may provide a treatment target for ICH therapy.
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business communication (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
red blood cells
surrounding brain tissue
inhibiting zinc insertion
ich-induced brain damage
technology description researchers
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium